Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAdministrative/Operational PolicyHumana Prior Auth & Notification Policy Update | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHumanaPolicy N/A

    Humana Dual Fully Integrated Illinois prior authorization and notification list

    Customize your policy alerts

    Sign up for all Humana policy alerts

    Know when Humana releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs prior authorization and notification requirements for medications and certain services for Humana Dual Fully Integrated (HMO D-SNP) Illinois members; affects participating providers, facilities, and delegated networks who must obtain prior authorization or provide notifications as specified.

    Policy Summary
    PayerHumana
    PolicyHumana Dual Fully Integrated Illinois prior authorization and notification list
    Policy CodePolicy N/A
    Change TypeAdministrative — routine update
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for listed medications and certain services via CoverMyMeds, phone (866-461-7273), or fax (888-447-3430) before providing care.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    90 daysno prior authorization required for active courses of treatment during first 90 days of new member enrollment
    3ways to initiate prior authorization (online, phone, fax)
    up to 6maximum diagnosis codes accepted per authorization request
    ‡HCPCS/NOC codes require NDC on claims
    1Transplant preauthorization review route noted

    Prior Authorization and Notification Coverage Criteria

    inv-01: Prior authorization and exceptions

    Medications and certain services listed require prior authorization; step therapy and coverage determinations follow Humana and CMS guidance.

    Medications administered in the provider's office, clinic, outpatient or home setting listed in the prior authorization list require prior authorization before being provided.
    Providers must obtain prior authorization in advance except for urgent/emergent services, which do not require prior authorization.
    For new members, prior authorization is not required for active courses of treatment during the first 90 days following enrollment; providers should follow applicable Medicare Advantage payment policy guidance and include appropriate documentation on claims.

    inv-02: Prior authorization / notification medication entries (examples)

    Medications listed require prior authorization or notification as indicated; see symbol legend for special conditions (e.g., ‡ NDC billing requirement, ** step therapy, †† transplant review).

    Policy Summary
    PayerHumana
    PolicyHumana Dual Fully Integrated Illinois prior authorization and notification list
    Policy CodePolicy N/A
    Change TypeAdministrative — routine update
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for listed medications and certain services via CoverMyMeds, phone (866-461-7273), or fax (888-447-3430) before providing care.
    SourceLink
    On This Page
    Prior Authorization and Notification Coverage CriteriaBilling and Coding (HCPCS / J-codes / NDC)Provider Responsibilities and Submission InstructionsSymbols and Key Definitions
    onabotulinumtoxinA (Botox) — billing code J0585; access the fax forms to request prior authorization or provide notification.
    ciltacabtagene autoleucel (Carvykti) — billing code Q2056; marked †† and routed to Humana National Transplant Network for review (submit via fax/phone/email as specified).

    inv-03: Prior authorization and billing criteria overview

    This section enumerates drugs that require prior authorization or notification and includes billing codes and special notes (step therapy, NDC billing requirement, transplant routing).

    Medications shown on the prior authorization list require prior authorization or notification as indicated on the list; providers should use the listed billing codes when submitting requests.
    Shared HCPCS and not otherwise classified (NOC) codes (marked '‡') require a corresponding National Drug Code (NDC) to be billed on all claims.
    Some medications are marked with '**' indicating step therapy is required through a Humana-preferred drug as part of preauthorization; review Humana's Part B Step Therapy Preferred Drug List for details.
    Items marked '††' will be reviewed by the Humana National Transplant Network; submission options (fax, phone, email) and contact information are provided in the list notes.

    inv-04: Prior authorization medication entries (partial)

    Medications listed require prior authorization or notification; special annotations (e.g., *, †, ‡, **, ††) apply as noted in the legend and list entries.

    ziconotide (Prialt) — billing code J2278; prior authorization or notification required as listed.
    sipuleucel-T (Provenge) — billing code Q2043; prior authorization or notification required as listed.
    Several medications include annotations: '*' = new preauthorization requirement; '†' = new-to-market drug; '‡' = shared HCPCS/NOC codes require an NDC on claims; '**' = step therapy required; '††' = transplant review routing.

    inv-05: Prior authorization/notification drug list

    Listed products require prior authorization or notification as indicated; follow submission instructions and billing rules in the notes for each entry.

    Vyondys 53 (golodirsen) — billing code J1429; prior authorization required as listed.
    Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) — billing code J9334; prior authorization required as listed.
    Yondelis (trabectedin) — billing code J9352; access the fax forms to request prior authorization or provide notification.

    Billing and Coding (HCPCS / J-codes / NDC)

    Examples of HCPCS/J-codes listed on medication tableHCPCS
    J9264Abraxane billing code (paclitaxel-nab)
    Q2055Abecma billing code (idecabtagene vicleucel)
    J3262Actemra IV (tocilizumab)
    Examples of medication billing codes appearing in this sectionHCPCS | CPT | mixedCovered
    J0585onabotulinumtoxinA
    Q2056ciltacabtagene autoleucel (Carvykti)
    J3392exagamglogene autotemcel (Casgevy)
    J1439ferric carboxymaltose (Injectafer)
    Representative J/C/A codes in this sectionmixed
    J1439Injectafer (ferric carboxymaltose)
    J9183gemcitabine (intravesical system)
    J9319romidepsin (Istodax)
    J9271pembrolizumab (Keytruda)
    J2350ocrelizumab (Ocrevus)
    J0219avalglucosidase alfa (Nexviazyme)
    A9513lutetium Lu 177 dotatate (Lutathera)
    Additional oncology/immunotherapy codesmixed
    J9299nivolumab (Opdivo)
    J9298nivolumab and relatlimab (Opdualag)
    A9607lutetium Lu 177 vipivotide tetraxetan (Pluvicto)
    examples from chunk 54HCPCS
    J2278ziconotide (Prialt)
    examples from chunk 55mixed
    Q2043sipuleucel-T (Provenge)
    J1304tofersen (Qalsody)
    C9399generic/unlisted HCPCS (used for some products)
    examples from chunk 73HCPCS
    J0218olipudase alfa (Xenpozyme)
    J0897denosumab (Prolia/Xgeva)
    Sample HCPCS/J-codes from listHCPCS
    J1429Vyondys 53
    J9334Vyvgart Hytrulo
    J9332Vyvgart IV
    J9153Vyxeos
    J1558Xembify (immune globulin)
    J0218Xenpozyme
    Additional HCPCS/J- and Q-codesHCPCS
    J9352Yondelis
    J9400Zaltrap
    Q5101Zarxio
    J0256Zemaira
    J9223Zepzelca
    inv-15: HCPCS NDC billing requirement
    RequirementAll shared HCPCS codes and not otherwise classified (NOC) codes require a corresponding National Drug Code (NDC) to be billed on all claims.
    ScopeApplies to shared HCPCS codes and NOC/unlisted HCPCS codes across the prior authorization list entries.
    Provider actionInclude the corresponding NDC on every claim when billing a code marked with the ‡ symbol.
    inv-16: NDC requirement for shared HCPCS/NOC codes
    RequirementAll shared HCPCS codes and not otherwise classified codes require a corresponding National Drug Code (NDC) to be billed on all claims.
    NotationEntries using the ‡ symbol indicate this NDC billing requirement.
    ImpactClaims for drugs with shared HCPCS/NOC codes may be denied or delayed if the NDC is not provided.

    Provider Responsibilities and Submission Instructions

    Denial Risk

    Consequences of noncompliance

    Prior authorization must be obtained in advance when required by this list. Failure to obtain required prior authorization may result in financial penalties to the practice, reduced benefits for the patient per the provider contract and the member's Evidence of Coverage, and claims subject to retrospective medical necessity review.

    • Services or medications provided without prior authorization may be denied or partially paid.
    • Providers should verify benefits and prior authorization requirements with Humana before providing services.
    Documentation Required

    Documentation requirements

    Submit all relevant clinical and administrative documentation with the prior authorization request to expedite review. Incomplete requests may delay determination and will be returned for additional information.

    • Include patient name, date of birth and Humana member ID.
    • Provide date of service or hospital admission and service location (outpatient, office, home, ASC, etc.).
    • List HCPCS codes and up to 6 diagnosis codes (primary and secondary).
    • Include facility TIN/NPI, rendering provider TIN/NPI, caller/requester name and phone number, and attending provider phone number.
    • Attach relevant clinical information (progress notes, labs, imaging, prior therapies).
    Step Therapy

    Step therapy for Medicare Part B medications

    Humana maintains a Medicare Part B Step Therapy Preferred Drug List (PDL). Review the Part B Step Therapy PDL and Humana coverage policies to confirm preferred drugs and cross-benefit strategies before submitting a request.

    • Affected Medicare Part B medications are noted with a step therapy indicator on the Medicare PAL.
    • Step therapy may require trials across benefits (Part B and Part D); check the Part B Step Therapy PDL for details.
    • Designation as preferred does not guarantee exemption from step therapy — follow specific coverage criteria.
    Prior Authorization

    How to request prior authorization (example entry)

    Example prior authorization entry fields — include these to help ensure a complete submission and faster processing.

    • Patient name, DOB, Humana member ID.
    • Date of actual service or hospital admission.
    • HCPCS code(s) and diagnosis code(s) (up to 6).
    • Service location and attending provider contact information.
    • Relevant clinical documentation supporting medical necessity.
    Note

    Prior authorization and transplant review note

    Some preauthorization requests (for transplant-related services) will be reviewed by the Humana National Transplant Network. Transplant preauthorization requests may be submitted by fax, phone, or email to the contacts below.

    • Transplant fax: 502-508-9300
    • Transplant phone: 866-421-5663, Monday–Friday, 7 a.m.–7 p.m. Central time
    • Transplant email: transplant@humana.com
    Note

    Legend / provider requirements

    Legend and provider requirements — symbols and special notes used throughout this list. Review these before submitting requests.

    • * New preauthorization requirement
    • † New-to-market drug addition
    • ‡ All shared HCPCS and NOC codes require a corresponding NDC to be billed on all claims
    • ** Step therapy required through a Humana-preferred drug as part of preauthorization
    • †† Preauthorization requests reviewed by Humana National Transplant Network
    Billing Rule

    Billing requirement for shared HCPCS/NOC codes

    When billing codes that are shared HCPCS or not otherwise classified (NOC) are used, a corresponding National Drug Code (NDC) must be submitted on all claims to identify the specific product administered.

    • This requirement applies to all shared HCPCS/NOC codes noted with the ‡ symbol on the list.
    • Failure to include the corresponding NDC on the claim may result in claim processing issues or denial.
    Prior Authorization

    How to request prior authorization (fax forms)

    Fax forms and submission channels: prior authorization for medications may be initiated via CoverMyMeds, phone, or fax. Access the fax request forms on Humana's prior authorization for professionally administered drugs website.

    • Online: CoverMyMeds (http://www.covermymeds.com/)
    • Phone: 866-461-7273 (TTY: 711), Monday–Friday, 8 a.m.–11 p.m. Eastern time
    • Fax: 888-447-3430 — request forms available on Humana's prior authorization for professionally administered drugs webpage
    • Many medication entries include links to fax forms for that specific drug on the notification list.

    Symbols and Key Definitions

    inv-32: Defined as a process requiring advance approval from the plan to determine whether an item or service will be covered.
    TermPrior authorization is a process through which the healthcare provider is required to obtain advance approval from the plan to determine whether an item or service will be covered.
    When requiredMedications delivered in-office, clinic, outpatient or home setting listed in this document require prior authorization before being provided or administered.
    ReferenceServices must be provided according to Medicare coverage guidelines; medical necessity applies.
    inv-33: ‡
    Symbol‡
    MeaningAll shared HCPCS codes and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims.
    ActionWhen you see the ‡ symbol on an entry, include the NDC on the claim for that product.
    inv-34: ††
    Symbol††
    MeaningPreauthorization requests marked with †† will be reviewed by the Humana National Transplant Network.
    SubmissionThese requests can be submitted by fax to 502-508-9300, by phone to 866-421-5663 (Mon–Fri, 7 a.m.–7 p.m. Central), or by email to transplant@humana.com.
    inv-35: **
    Symbol**
    MeaningStep therapy is required through a Humana-preferred drug as part of preauthorization.
    Provider noteEntries marked with ** indicate the member must try the Humana-preferred agent(s) before the requested drug will be approved under prior authorization criteria.
    inv-36: *
    Symbol*
    MeaningIndicates a new preauthorization requirement.
    Provider actionVerify prior authorization requirements for newly flagged products before providing service.
    inv-37: ‡ (duplicate at other chunk)
    Symbol‡
    MeaningThe ‡ marker denotes that shared HCPCS and NOC codes require a corresponding NDC on claims (reiterated in multiple sections).
    ExampleSee entries such as lanreotide ‡ (billing code J1930) where an NDC must accompany the HCPCS/NOC code.
    inv-38: ** (duplicate at other chunk)
    Symbol**
    MeaningIndicates step therapy required through a Humana-preferred drug as part of preauthorization (appears alongside specific drug entries).
    ExamplePembrolizumab ** (billing codes J9271/J9277) is listed with ** indicating step therapy applies.
    inv-39: †† (duplicate at other chunk)
    Symbol††
    MeaningIndicates preauthorization requests will be reviewed by the Humana National Transplant Network; contact details provided for submission.
    ExampleProducts such as Lantidra †† ‡ (C9399, J3490, J3590) are routed to the transplant network for review.
    inv-40: * (duplicate at other chunk)
    Symbol*
    MeaningIndicates a new preauthorization requirement (appears throughout the document where products are newly added to the PA list).
    Cross-referenceSee overall legend (How to request prior authorization) for definition and implications of '*'.
    inv-41: ‡ (NDC billing requirement)
    RequirementAll shared HCPCS and not otherwise classified codes require a corresponding National Drug Code to be billed on all claims (‡).
    PurposeEnsures accurate drug identification when multiple products share the same HCPCS or unlisted code.
    Provider actionInclude NDC on claim submissions for any entry marked with ‡ to avoid claim processing issues.
    inv-42: ** (step therapy)
    Symbol**
    MeaningStep therapy required through a Humana-preferred drug as part of preauthorization; noted in the legend and beside applicable drugs.
    ActionFollow Humana's Part B Step Therapy Preferred Drug List where indicated prior to approval of the requested agent.
    inv-43: †† (transplant review)
    Symbol††
    MeaningPreauthorization requests marked †† are reviewed by the Humana National Transplant Network.
    ContactSubmit via fax to 502-508-9300, by phone at 866-421-5663 (Mon–Fri, 7 a.m.–7 p.m. Central), or email transplant@humana.com.
    inv-44: * / † (new requirement / new-to-market)
    Symbols* = new preauthorization requirement; † = new-to-market drug addition
    ImplicationEntries marked with * or † indicate changes to authorization requirements or newly marketed drugs; verify requirements before service.
    Provider actionCheck the entry legend and follow submission instructions for new or newly marketed products.
    inv-45: Shared HCPCS/NOC codes require a corresponding National Drug Code (NDC) to be billed on all claims.
    RequirementShared HCPCS/NOC codes require a corresponding National Drug Code (NDC) to be billed on all claims.
    NotationDenoted by the ‡ symbol in the medication list and legend.
    ReasonEnsures specific product identification when multiple products share the same HCPCS or unlisted code.
    inv-46: Step therapy required through a Humana-preferred drug as part of preauthorization.
    RequirementStep therapy is required through a Humana-preferred drug as part of prior authorization when entries are marked with **.
    ScopeApplies to certain Medicare Part B medications listed; see Humana's Part B Step Therapy Preferred Drug List for preferred agents.
    Provider actionDocument trials of preferred agents as required when submitting PA requests for drugs with **.
    inv-47: New preauthorization requirement.
    Change typeNew preauthorization requirement added to the prior authorization list (entries marked with *).
    Provider actionConfirm authorization is obtained for items newly requiring PA before providing the service.
    Effective dateEffective date shown in the document header: 07/01/2026.
    inv-48: New-to-market drug addition.
    Change typeNew-to-market drug additions appear marked with †; these are newly listed products that may require PA.
    Provider actionFor † entries, review product-specific submission requirements and include required clinical documentation.
    ExampleLegend notes † indicates a new-to-market drug addition.
    inv-49: Preauthorization requests reviewed by the Humana National Transplant Network.
    RoutingPreauthorization requests for products marked †† are reviewed by the Humana National Transplant Network.
    Submission methodsFax: 502-508-9300; Phone: 866-421-5663 (Mon–Fri, 7 a.m.–7 p.m. Central); Email: transplant@humana.com.
    ImplicationTransplant-related PAs follow a separate review workflow managed by the transplant network.